SUPRIYA · Healthcare · Biotechnology
Composite scorecard: 57/100 — Quality 81 · Valuation 14 · Momentum 72
| Share price | ₹837.30 |
| Market cap | ₹6,878 Cr |
| P/E ratio | 32.9 |
| P/B ratio | 5.7 |
| ROCE | 22.4% |
| Dividend yield | 0.12% |
| Book value | ₹148.77 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹828 Cr | ₹209 Cr | 32.1% |
| 2025 | ₹696 Cr | ₹188 Cr | 34.5% |
| 2024 | ₹557 Cr | ₹119 Cr | 28.3% |
| 2023 | ₹451 Cr | ₹90 Cr | 25.6% |
| 2022 | — | — | — |
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depres